How often should laboratory monitoring occur for patients receiving INH?

Patients receiving isoniazid (INH) require regular laboratory monitoring, typically conducted every month, as this helps ensure their safety and the effectiveness of treatment. INH can have significant effects on the liver, and regular monitoring allows for the early detection of potential hepatotoxicity.

This monitoring is crucial because it involves checking liver function tests, which can indicate whether the medication is adversely affecting the liver. By performing these tests monthly, healthcare providers can adjust dosages or switch medications as necessary, ensuring that patients maintain optimal health while undergoing treatment for tuberculosis.

While some options suggest less frequent monitoring—such as only in the first month, every six months, or annually—these intervals may not sufficiently capture any liver issues that develop early in the treatment process. Monthly monitoring aligns with best practices for managing patients on INH, allowing for timely interventions when needed.